Navigation Links
ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
Date:8/19/2007

SCOTTSDALE, Ariz., Aug. 16 /PRNewswire-FirstCall/ -- IR BioSciences Holdings, Inc. (OTC Bulletin Board: IRBO) today released a letter to shareholders from Chairman and CEO Michael K. Wilhelm. The purpose of the letter is to provide an update to its shareholders on its subsidiary ImmuneRegen BioSciences' past year of progress in the infectious disease and disaster preparedness sectors. ImmuneRegen today has also filed a Form 8-K containing the shareholder letter with the Securities and Exchange Commission. The Form 8-K will be available on ImmuneRegen's website at http://www.immuneregen.com. The text of the letter is contained below:

Dear Shareholder,

The previous year has been a noteworthy one for ImmuneRegen BioSciences. Our scientific and business activities have accelerated, and the company has recently announced several noteworthy achievements and events such as acquisition of study results, formation of collaborative and co-development relationships as well as presentations at conferences and to the FDA and NIH. The response by these agencies of the Department of Health and Human Services remains quite positive as we continue to deliver additional data in multiple areas of both scientific and product development interest and having potential commercial appeal.

Current research programs include microbiological infection such as anthrax bacillus, and influenza (including avian influenza vaccine adjuvancy), in addition to radiation exposure (to both lethal and sub-lethal/therapeutic doses). Results of our influenza studies indicate that Viprovex(R) lowers viral load 90-99% in nose and lungs of treated animals, as well as lowers the magnitude of the virus-induced decreases in body weight and temperature. These studies also indicate that Viprovex decreases the inflammatory reaction in the lungs of infected animals, even in the presence of Roche's influenza treatment and preventative, Tam
'/>"/>

SOURCE ImmuneRegen BioSciences, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related biology technology :

1. Perscitus Biosciences secures $250K Commerce loan
2. Wisconsin biosciences rise to the challenge
3. Quintessence Biosciences advances cancer drug
4. Quintessence Biosciences names new president
5. Caden Biosciences may signal critical mass
6. Wisconsin start up Primorigen Biosciences corrals out-of-state investment
7. WARF signs licensing pact with BD Biosciences
8. Fisher Biosciences contracts with Madison-based GenTel BioSurfaces
9. State awards QRG Biosciences development grant
10. EMD Biosciences partners with European biotech company
11. Quintessence Biosciences forms cancer therapeutic advisory board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)... April 23, 2015 Proove ... Personalized Medicine, is excited to announce the launch ... . This profile assesses 62 genetic variations to ... information for commonly prescribed non-opioid pain medications, namely ... Neurontin), alprazolam (brand name Xanax) and acetaminophen (brand ...
(Date:4/23/2015)... NY , April 23, 2015 /PRNewswire/ - Crystal ... an Executive Informational Overview ® (EIO) on Aeterna ... 52-page report is available on Crystal Research Associates, website ... on Aeterna Zentaris, website at www.aezsinc.com . ... into a specialty biopharmaceutical company in oncology, endocrinology, and ...
(Date:4/22/2015)... 23, 2015  The Heinz Family Foundation today ... Heinz Awards, which will present unrestricted cash awards ... their creativity and determination in finding solutions to ... This year,s recipients include a prolific cartoonist whose ... and personal relationships; two former Marines who are ...
(Date:4/22/2015)... 2015   MPIRICA Health Inc. , a ... Series A financing from the McQuinn Trust, an ... consumer and employer awareness of MPIRICA.com, delivering easily ... 4,800 U.S. hospitals. "As a patient ... concerned about choosing the hospital and surgeon most ...
Breaking Biology Technology:Proove Biosciences Launches World’s First Test to Predict Responders to Commonly Prescribed Non-Opioid Pain Medications 2Proove Biosciences Launches World’s First Test to Predict Responders to Commonly Prescribed Non-Opioid Pain Medications 3Crystal Research Associates, LLC Issues Executive Informational Overview (EIO) on Aeterna Zentaris Inc. 2Crystal Research Associates, LLC Issues Executive Informational Overview (EIO) on Aeterna Zentaris Inc. 3From a Scientist Who Develops Human Microlivers to a New Yorker Cartoonist Who Masterfully Depicts the Humor and Heartbreak of Everyday Life: The 20th Heinz Awards Honors Six Changemakers 2From a Scientist Who Develops Human Microlivers to a New Yorker Cartoonist Who Masterfully Depicts the Humor and Heartbreak of Everyday Life: The 20th Heinz Awards Honors Six Changemakers 3From a Scientist Who Develops Human Microlivers to a New Yorker Cartoonist Who Masterfully Depicts the Humor and Heartbreak of Everyday Life: The 20th Heinz Awards Honors Six Changemakers 4From a Scientist Who Develops Human Microlivers to a New Yorker Cartoonist Who Masterfully Depicts the Humor and Heartbreak of Everyday Life: The 20th Heinz Awards Honors Six Changemakers 5From a Scientist Who Develops Human Microlivers to a New Yorker Cartoonist Who Masterfully Depicts the Humor and Heartbreak of Everyday Life: The 20th Heinz Awards Honors Six Changemakers 6MPIRICA Health Inc. Secures $1.6M to Promote FICO-Like Quality Scores for Surgeries 2
... capable of some pretty remarkable things when they,re placed ... can even produce electricity. Driven by the vision ... team of University of Houston scientists has set out ... known as piezoelectrics, which naturally produce electricity when literally ...
... , , , ... Inc. (NYSE: BEC ) announced today that its Board of ... of outstanding common stock, payable on August 24, 2009 to all stockholders ... consecutive, quarterly payout of dividends. , , (Logo: ...
... , , ... Amgen (Nasdaq: AMGN ) and GlaxoSmithKline (GSK) today announced ... monoclonal antibody denosumab for postmenopausal osteoporosis (PMO) in Europe, Australia, New ... Amgen will commercialize the drug for PMO and oncology in ...
Cached Biology Technology:Charging ahead: University of Houston team revealing secrets of electricity-producing materials 2Charging ahead: University of Houston team revealing secrets of electricity-producing materials 3Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO) 2Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO) 3Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO) 4Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO) 5Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO) 6Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO) 7
(Date:4/1/2015)... Conn. , Apr. 1, 2015  NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce ... of Wocket smart wallets is underway to early access ... access group includes usage at retail outlets including Walmart, ... Pharmacy. Users report Wocket was accepted at all outlets ...
(Date:3/31/2015)... YORK , March 31, 2015   Guidepoint ... the launch of the Post-Surgical Pain Management TRACKER, part ... products tracking usage trends in the medical device and ... access to data including treatment volumes, market share, and ... the pain associated with joint surgery. The ...
(Date:3/24/2015)... Mar. 24, 2015 Research and Markets ... "Global Iris Recognition Market 2015-2019" report to ... Iris Recognition market to grow at a CAGR of ... report covers the present scenario and the growth prospects ... 2015-2019. To calculate the market size, the report considers ...
Breaking Biology News(10 mins):NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2
... ARTICLE #1 FOR IMMEDIATE RELEASE Evidence that inexpensive ... Energy & Fuels Amid sticker-shock fuel prices, researchers ... tests verifying that a simple, inexpensive device attached to a ... to 20 percent. That translates into several more precious miles ...
... They are used in cancer treatments, automobile sensors, ... production. However, until recently, scientists couldn,t create the ... impacts on the environment. A new method, created ... only eliminates any negative environmental impact, but also ...
... and his collaborators have developed a way to mass-produce ... less expensive. Metcalf set out to ... as phosphonates, is made in nature by bacteria. He ... have antibiotic properties. Recently, Metcalf and his lab successfully ...
Cached Biology News:American Chemical Society's Weekly PressPac -- Sept. 24, 2008 2American Chemical Society's Weekly PressPac -- Sept. 24, 2008 3American Chemical Society's Weekly PressPac -- Sept. 24, 2008 4American Chemical Society's Weekly PressPac -- Sept. 24, 2008 5American Chemical Society's Weekly PressPac -- Sept. 24, 2008 6American Chemical Society's Weekly PressPac -- Sept. 24, 2008 7American Chemical Society's Weekly PressPac -- Sept. 24, 2008 8MU scientists go green with gold, distribute environmentally friendly nanoparticles 2New way to make malaria medicine also first step in finding new antibiotics 2New way to make malaria medicine also first step in finding new antibiotics 3New way to make malaria medicine also first step in finding new antibiotics 4
... Biotin label transfer is fast emerging ... interaction discovery and confirmation. Until now, only ... targeted with label transfer reagents such as ... chain analog, Mts-Atf-LC-Biotin, are exciting additions to ...
... of 3 siRNAs specifically targeted to your ... product. The siTrio reagent guarantees you get ... gene when used under standard conditions (100 ... optimal transfection with one of B-Bridges controls). ...
... a compact benchtop and stackable multi-function ... with a large display screen to ... Air circulation inside to evenly distribute ... be easily calibrated from the microprocessor ...
...
Biology Products: